vimarsana.com

Latest Breaking News On - Net loss attributable to synthetic biologics inc - Page 1 : vimarsana.com

Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results

11.08.2022 - -Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business .

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.